Safety Study of OPC-12759 Ophthalmic Solution

Otsuka Pharmaceuticals Co., Ltd.0 个研究点目标入组 100 人开始时间: 2011年10月25日最近更新: 2023年10月17日

适应症

试验速览

2% OPC-12759 ophthalmic solution had no particular safety problems in the treatment for dry eye.

•1.Gender: Male or Female
•2.Age: 20 years and older (at the time of informed consent)
•3.BMI : {body weight (kg) / [height (m)] 2 } must be 17.6 or greater, and less than 26.4 kg/m2

•1.Presence of ocular disorder
•2.Intraocular pressure of 21mmHg or higher
•3.Corrected visual acuity of less than 1.0
•4.Dysfunction of nasolacrimal duct or history of surgery related to nasolacrimal duct or eye lid which affects the nasolacrimal outflow
•5.History of refractive surgery
•6.History of other ocular surgeries within 12 months
•7.Those who cannot discontinue the use of contact lenses from the 1st dose to 5-hour-post-dose.

发起方

Otsuka Pharmaceuticals Co., Ltd.